Economics
Capital-efficient drug creation.
Traditional pharma spends capital on infrastructure. EvoPharma spends capital to create knowledge and IP-protected therapeutic assets.
Cost targets
Lean successful program
$2–3M
Protected IP, optimized compounds, strong in vitro evidence, and initial in vivo proof-of-concept.
Comprehensive package
$5–10M
Expanded validation, stronger patent coverage, ADME/safety profiling, and better partnership readiness.
Three-program portfolio
$6–9M lean / $15–30M robust
Aging, oncology, PCSK9, and GLP-1 programs advanced through staged CRO execution.
Funding roadmap
Founder + early private capital$250k–$1M for company formation, IP protection, initial CRO synthesis, and first validation data.
Pre-seed financing$2–5M for lead optimization, expanded validation, ADME/early safety, and animal proof-of-concept.
Seed / strategic partnership$10–30M or pharma partnership to advance the strongest program toward a robust preclinical package, licensing, or IND-enabling work.